---

Dantrolene - Comprehensive Pharmacology

---

1. Drug Group / Classification

---

2. Chemical Structure

• Chemical name: 1-[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione
• Molecular formula: C₁₄H₁₀N₄O₅
• Molecular weight: 314.26 g/mol
• Key structural features:
  • A hydantoin ring (imidazolidinedione) - the pharmacophore responsible for muscle relaxant activity
  • A furan ring linked via a methylene amino bridge
  • A para-nitrophenyl group attached to the furan ring
• The molecule is highly lipophilic and has very low water solubility - this is its major formulation challenge

---

3. Formulation and Dilution

Intravenous Formulations

• Ryanodex (Ryandox in some markets) uses nanosuspension + lyophilized technology for rapid reconstitution and faster onset of effect
• Mannitol is added as a co-solubilizer and osmolality adjusting agent
• Due to the high pH (~9.5-10.3), dantrolene is a tissue/vein irritant - administer through a large-bore or central venous line to minimize phlebitis

Oral Formulation

• Dantrium capsules - 25 mg, 50 mg, 100 mg capsules
• Trade names: Dantrium (oral), Revonto (IV), Ryanodex (IV nanosuspension), Ryandox

---

4. Available Forms in Market

---

5. Routes of Administration

• Intravenous (IV): Used in acute emergencies (malignant hyperthermia, NMS crisis)
• Oral: Used for chronic spasticity management, and prophylaxis before surgery in MH-susceptible patients

---

6. Dosage

Malignant Hyperthermia (MH) - Acute Treatment

• Initial dose: 2.5 mg/kg IV bolus, repeated every 5 minutes
• Maximum dose: 10 mg/kg (some authorities allow up to 20-30 mg/kg in refractory cases)
• Endpoint: termination of the episode (temperature falling, ETCO₂ decreasing, rigidity resolving)
• Maintenance (post-crisis): 1 mg/kg IV every 4-6 hours for 24-48 hours to prevent recrudescence (MH can recur within 6.5-24 hours of the initial episode)

MH Prophylaxis (Pre-operative)

• 2.5 mg/kg IV over 1 minute, approximately 75 minutes before surgery
• Note: Prophylaxis is generally unnecessary if non-triggering agents are used instead

Chronic Spasticity (Oral)

• Start at 25 mg once daily for 7 days
• Increase by 25 mg increments every 7 days
• Typical maintenance: 100 mg three to four times daily
• Maximum dose: 400 mg/day

Neuroleptic Malignant Syndrome (off-label IV)

• 1-2.5 mg/kg IV, may repeat as needed

---

7. Mechanism of Action

1. Normally, an action potential in a motor neuron activates the dihydropyridine receptor (DHPR) in the T-tubule membrane
2. DHPR mechanically activates the ryanodine receptor type 1 (RyR1) - the Ca²⁺ release channel on the SR
3. Ca²⁺ floods from the SR into the cytoplasm → binds troponin C → actin-myosin cross-bridging → muscle contraction (excitation-contraction coupling, ECC)

• Binds to RyR1 (either directly or via calmodulin/accessory proteins) and inhibits Ca²⁺ release from the SR
• Requires Mg²⁺ as a cofactor for full inhibitory effect (2017 discovery)
• Also attenuates CaV1.1-mediated depolarization-triggered Ca²⁺ entry which is exacerbated in MH-susceptible muscle
• Result: intracellular Ca²⁺ falls → ECC is uncoupled → muscle relaxation
• Does NOT block the neuromuscular junction, does NOT affect nerve conduction
• Acts only on skeletal muscle (RyR1); cardiac muscle (RyR2) and smooth muscle (RyR3) are relatively spared

---

8. Pharmacokinetics

---

9. Pharmacodynamics

• Skeletal muscle: Generalized dose-dependent weakness; at 2.4 mg/kg, maximum twitch depression occurs in healthy volunteers - hence respiratory support may be needed
• Cardiac muscle: Minimal effect at therapeutic doses (RyR2 relative insensitivity)
• Smooth muscle: Some inhibition of intestinal smooth muscle (explains GI side effects)
• CNS: Minimal direct effect (peripheral action), though CNS depression can occur at high doses
• Metabolic: Reduces heat production by decreasing ATP-consuming muscle contraction in MH
• Drug interaction with calcium channel blockers: Verapamil + dantrolene → dangerous hyperkalemia and hypotension - combination is contraindicated. Calcium channel blockers (nifedipine, verapamil, diltiazem) can independently increase intracellular Ca²⁺ in skeletal muscle, partially overcoming dantrolene's effect.

---

10. Indications

FDA-Approved

1. Malignant Hyperthermia (MH) - Acute treatment: Life-threatening hypermetabolic crisis triggered by volatile anesthetics or succinylcholine; dantrolene reduced MH mortality from ~80% (1960s) to <10% today
2. MH Prophylaxis: Pre-operative IV in confirmed MH-susceptible patients (though avoidance of triggering agents is preferred)
3. Chronic spasticity associated with upper motor neuron disorders: spinal cord injury, stroke, cerebral palsy, multiple sclerosis

Off-Label Uses

1. Neuroleptic Malignant Syndrome (NMS): Antipsychotic-induced hypermetabolic state with hyperthermia, rigidity, altered consciousness
2. Thyroid storm: Reduces hyperthermia
3. Heat stroke: Reduces skeletal muscle thermogenesis (though evidence from RCTs is limited/mixed)
4. Ecstasy (MDMA) intoxication: Associated with hyperthermia and muscle rigidity
5. Serotonin syndrome (adjunct, limited evidence)

---

11. Contraindications

Absolute (IV dantrolene)

• None - for acute MH treatment, there are NO absolute contraindications; the risk of withholding dantrolene in MH invariably exceeds any risk from the drug

Oral dantrolene

• Active hepatic disease (cirrhosis, hepatitis B/C, NASH) - black box warning for hepatotoxicity
• Patients who require upright posture and balance for daily function (e.g., ambulatory patients with mild spasticity - muscle weakness may be disabling)

Relative / Caution

• Pregnancy (FDA Category C): Use only when benefits outweigh risks; in acute MH, use is justified
• Breastfeeding: Avoid, or discontinue breastfeeding for 48 hours after last dose
• Co-administration with verapamil or other calcium channel blockers: Risk of hyperkalemia and cardiac arrest
• Co-administration with estrogens: Increased risk of hepatotoxicity (especially in women >35 years)
• Neuromuscular diseases (myasthenia gravis, muscular dystrophy): Exacerbation of weakness

---

12. Adverse Effects

Acute / IV Administration

Chronic / Oral Administration

• Hepatotoxicity (most serious - BLACK BOX WARNING): Overt hepatitis, fatal liver failure; monitor LFTs throughout therapy; most common in females, age >35, and concurrent estrogen use
• Drowsiness, dizziness, malaise
• Diarrhea (dose-limiting)
• Nausea, vomiting
• Weakness, fatigue
• Rare: pleural effusion with eosinophilic exudate (develops 2 months - 12 years after initiation; unilateral, may be febrile with pleuritic chest pain)
• Photosensitivity

---

13. Special Points

1. Only specific drug for MH: Dantrolene remains the only medication specifically effective in treating and preventing malignant hyperthermia. All facilities administering MH-triggering agents (volatile anesthetics, succinylcholine) must stock dantrolene on-site at all times (MHAUS requirement).
2. Formulation challenge: Low water solubility is the main pharmacological limitation. The classic 20 mg vial requires 60 mL sterile water - preparing an initial 2.5 mg/kg dose for a 70 kg patient requires ~9 vials (180 mg), each mixed individually. This is time-consuming in an emergency, necessitating assistance.
3. Ryanodex advantage: The 250 mg/vial nanosuspension reconstitutes in 5 mL and significantly shortens time-to-treatment, particularly important when only one provider is available.
4. Recrudescence risk: MH can recur in up to 50% of cases, typically within 6.5 hours (but up to 16 hours). Maintenance dosing for 24-48 hours post-crisis is mandatory.
5. Calcium channel blocker interaction: Verapamil combined with dantrolene can cause fatal hyperkalemia and cardiac arrest. MHAUS explicitly discourages use of any calcium channel blockers when dantrolene has been given.
6. Ondansetron caution: As a 5-HT₃ antagonist, ondansetron may increase serotonin at 5-HT₂A receptors; in MH-susceptible individuals, 5-HT₂A agonism may potentially precipitate MH - use with caution in this context.
7. Phlebitis: Given its high pH, administer through a central venous line or large-bore peripheral IV.
8. Magnesium co-dependence: 2017 research showed dantrolene requires Mg²⁺ for optimal RyR1 inhibition - monitoring and correcting magnesium levels during MH management is important.
9. Hepatotoxicity monitoring (oral): Baseline LFTs before starting; repeat every 1-3 months. Discontinue immediately if liver enzymes rise significantly.
10. Spasticity use is limited to non-ambulatory patients: Because peripheral skeletal muscle weakness is an expected pharmacodynamic effect, oral dantrolene for spasticity should be used only in patients who do not rely on muscle tone for mobility.

---

Quick Reference Summary Table

---